

IMMUNOTHERAPIES

CAR-T: CAR-T Constructs with NKG2D Receptor Signaling Domains	22MA027
TILs: aAPCs that expresses an anti-CD3 scFv transmembrane to determine the cytotoxicity of TILs	21MB083
CLEC12A: Novel CLEC12A scFv Targeting CAR-T cells for Acute Myeloid Leukemia Immunotherapy	21MB064N
KRAS: Platform Technology: Dimeric IgA Therapeutic Antibody for Intra-Tumoral Targeting of Mutant KRAS	21MB061
MDSC: Method of using Oral-L-Fucose to reduce immunosuppressive effect of Myeloid Derived Suppressor Cells (MDSCs)	21MA028N
CD40: CD40 Agonist improves ex-vivo TIL expansion for immunotherapy	21MA018
ITAM: Human ITAM Mutated Variants For Better Intracellular Signaling Domains For Gamma-Delta CAR T-Cell Activation	21MA008N
ESR1: Mutated Estrogen Receptor Neoantigen Peptide-Pulsed Type I Dendritic Cell (DC1) Vaccine Therapy to Treat Metastatic ER-positive Breast Cancer	20MB062
NOTCH: Single-domain antibodies (nanobodies) targeting the notch ligand DLL4 to Disrupt the interaction of DLL4 and Notch1 for GVHD	20MB053N
CD33 CD123 NKG2DL: Bispecific Gamma Delta CAR-T Cells that Recognize CD33, CD123 and NKG2D Ligands for the Treatment of Acute Myeloid Leukemia	20MB050N
OR2H1 or OR5V1: Olfactory Receptor Targeting Chimeric Antigen Receptor Expressing T cell (CAR-T) for Solid Tumors	20MA027
CD33 CD123: Novel Bispecific CD33 CD123 scFv CAR-T Cells for Acute Myeloid Leukemia Immunotherapy	20MA024
HER-2: Combination Therapy of a HER2-DC1 Dendritic Cell Cancer Vaccine and a Probiotic	20MA016N
TILs: 12 Chemokine Gene Expression Signature to Increase the Efficacy of Manufacturing Tumor Infiltrating Lymphocytes	20MA013N
CAR-T: D99/CLEC12A AND gated Bispecific CAR-T for the Treatment of AML	20MA009
PERK, IRE1: Method of Enhancing Immunotherapy Using ER Stress Pathway Inhibitors	20MA005
PGC-1α: CAR T Cells Engineered to Express PGC-1 alpha Demonstrate Enhanced Metabolic Fitness	19MB066

Charlie Shaw PhD
 Associate Director, Licensing
 Charlie.Shaw@Moffitt.org
 (813) 745-6639

Praba Soundararajan PhD
 Intellectual Property Manager
 Praba.Soundararajan@Moffitt.org
 (813) 745-6776

Sayantan Purkayastha, MS
 Industry Alliance Development Specialist
 Sayantan.Purkayastha@Moffitt.org
 (813) 745-0724

IMMUNOTHERAPIES

PGC-1α: N-Terminal Mutant PGC-1α Overexpression Enhances Metabolic Fitness Reducing CAR-T Exhaustion while Maintaining Proliferative Capacity	19MB066T2
TILs: Fucose increases tumor cell HLA-DRB1 expression increasing CD4+ T-cell activation with synergistic tumor killing activity with anti-PD1 checkpoint inhibitors	19MB049N
Antibodies: Fully Human Anti-BDNF Antibodies	19MB048N
Antibodies: Fully Human Anti-TSPAN7 Antibodies	19MB047N
T-Bet: T-Bet Transcription Factor Armed CAR-T Cells Maintain Memory Phenotypes and Rescue CD4 Cells Leading to Increased Persistence	19MA035N
EGFR, MUC1: Bispecific CAR-T Cell Constructs (Chimeric Antigen Receptors) that Recognize EGFR and MUC1 for the Treatment of Lung Cancer	19MA033N
Bispecific T-Cell Engagers: B-Cells Engineered to Express Bispecific T-Cell Engagers Result in Longer Engager Half Lives	19MA029N
NOTCH: Modified Delta-like 4 (DLL4) Ligands with Increased Affinity for Multiple Notch Receptors Enhance the Efficacy of Adoptive T-cell Immunotherapy	19MA026N
aAPC: Artificial Antigen-Presenting Cells Expressing NKG2D Ligands for Producing Anti-NKG2D CAR-T Cells	19MA022N
NKG2D-Ligand: Enhancing Carcinoma Infiltration by NKG2D-Ligand Targeted CAR-T Cells by Co-Expression of the Chemokine Receptor CX3CR1	19MA015NT2
GPC3: Enhancing Carcinoma Infiltration by Anti-GPC3 Targeted CAR-T Cells by Co-Expression of the Chemokine Receptor CX3CR1	19MA015N
B-RAF: Method of Combination Therapy Using B-Raf Inhibitors in Combination with TILs for B-Raf Inhibitor Resistant Melanomas	19MA007
TILs: Enhancing the Anti-Tumor Immunity of TILs by Inhibiting Sirt2	18MB078
CD277: Method of using anti-CD277 antibodies to treat cancer	18MB072N
Antibodies: Fully Human Anti-LAG3 Antibodies	18MB062N
Antibodies: Fully Human anti-PD1 Antibodies	18MB061

Charlie Shaw PhD
Associate Director, Licensing
Charlie.Shaw@Moffitt.org
(813) 745-6639

Praba Soundararajan PhD
Intellectual Property Manager
Praba.Soundararajan@Moffitt.org
(813) 745-6776

Sayantan Purkayastha, MS
Industry Alliance Development Specialist
Sayantan.Purkayastha@Moffitt.org
(813) 745-0724

IMMUNOTHERAPIES

Brain Mets: CAR-T Cell Constructs with Phage Display Derived Peptide Oligomers that Recognize Lung Cancer Brain Metastases	18MB059
Glioma: Glioma Stem Cell Targeting CAR-T Cell Constructs with Phage Display Derived Peptide Oligomers	18MB054
Suicide Switch: CAR-T Cells Designed to Self-Destruct if Patient Shows Signs of Toxicity Including GVHD, Cytokine Release Syndrome (CRS), and Neurotoxicity	18MB049N
TLR9 Ligand Trap: TLR9-IgG4 Fusion Protein to Neutralize Innate Immune Activation and Chronic Inflammation Contributing to MDS Pathogenesis	18MB048N
Inflammasome: Small-Molecule Pyrin-Domain Targeted NLRP3 Inflammasome Inhibitors to Neutralize Pyroptotic Cell Death Contributing to MDS Pathogenesis	18MB044N
PSCA: Gamma Delta CAR-T Cell Constructs (Chimeric Antigen Receptors) that Recognize PSCA for CAR by Killing Bone Metastatic Prostate Cancer Cells	18MA037
TILs: Method of Using a Demethylating Agent to Enhance STING Expression and TIL Anti-Tumor Activity in Melanoma	18MA034N
TILs: TILs Modified with CAR Constructs Result in CAR-TILs for Cancer Therapy	18MA033
NKG2D ligands: NKG2D Chimeric Antigen Receptor CAR-T Cells for Acute Myeloid Leukemia Immunotherapy	18MA023
aAPC: Artificial Antigen-Presenting Cells with Heparin-Binding Domain and Protein L for Producing CAR-T Cells	18MA019N
TILs: CD40 Agonist Improves ex-vivo TIL Expansion for Immunotherapy	18MA018
TILs: Method to Increase TILs by Administering Fucose to a Patient	17MB048
CD99: Novel CD99 scFv Targeting CAR-T cells for Acute Myeloid Leukemia Immunotherapy	17MA042
CD99 CLEC12A: Novel Bispecific CD99 CLEC12A scFv CAR-T Cells for Acute Myeloid Leukemia Immunotherapy	17MA042T2N
CLEC12A: Novel CLEC12A scFv Targeting CAR-T cells for Acute Myeloid Leukemia Immunotherapy	17MA041
Inflammasome: Stapled Peptides NLRP3 Inflammasome Inhibitors to Neutralize Pyroptotic Cell Death Contributing to MDS Pathogenesis	17MB037

Charlie Shaw PhD
 Associate Director, Licensing
 Charlie.Shaw@Moffitt.org
 (813) 745-6639

Praba Soundararajan PhD
 Intellectual Property Manager
 Praba.Soundararajan@Moffitt.org
 (813) 745-6776

Sayantana Purkayastha, MS
 Industry Alliance Development Specialist
 Sayantan.Purkayastha@Moffitt.org
 (813) 745-0724

IMMUNOTHERAPIES

CD123: Novel CD123 scFv Targeting CAR-T cells for Acute Myeloid Leukemia Immunotherapy	17MA031
CD33, CD123: Bispecific CAR-T Cell Constructs that Recognize CD33 and CD123 for the Treatment of Acute Myeloid Leukemia	17MA030T2
CD33: Novel CD33 scFv Targeting CAR-T cells for Acute Myeloid Leukemia Immunotherapy	17MA030
TILs: Simple and Rapid Method for Culture of TILs from Melanoma Tumor Fragments or Core Needle Biopsies of Solid Tumors	17MA012
CD3-CD28: Bispecific Antibody for the Generation of CAR-T cells for Cancer Immunotherapy	17MA007
IL-13Rα2: CAR-T Cell Constructs (Chimeric Antigen Receptors) that Recognize IL-13R α 2	16MB069
TAG72: CAR-T Cell constructs (chimeric antigen receptors) that Recognize TAG72	16MB057
aAPC: Artificial Antigen-Presenting Cells for Expanding TILs/MILs in Cancer Immunotherapy	16MB050
aAPC: Artificial Antigen-Presenting Cells Expressing CD3, CD28 and a Heparin-Binding Domain for Producing CAR-Ts	16MB049
TLS: Method of Using Chitosan Hydrogels with Chemokine-Releasing Microparticles or Stromal Cells to Bioengineer Tertiary Lymphoid Structures to Enhance the Immune System for Cancer Therapy	16MA028N
TLR9: CAR-T Cell Constructs (Chimeric Antigen Receptors) that Recognize TLR9	16MA025
TIM3 Ligand Trap: TIM-3-IgG4 Fusion Protein for the Treatment of Anemia in Low- or Intermediate (Int)-risk MDS Patients	16MA001
Bromodomain: Ex vivo Activation and Expansion of Antigen Specific T cells in the Presence of a Bromodomain Inhibitor	14MB100N
Cancer Vaccine: Full-Length Variant Survivin Vaccine Potentiates Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma	14MB098
TAG72-CD3: Bispecific T-Cell Engager for Targeted Cancer Immunotherapy	14MB072

Charlie Shaw PhD
Associate Director, Licensing
Charlie.Shaw@Moffitt.org
(813) 745-6639

Praba Soundararajan PhD
Intellectual Property Manager
Praba.Soundararajan@Moffitt.org
(813) 745-6776

Sayantana Purkayastha, MS
Industry Alliance Development Specialist
Sayantan.Purkayastha@Moffitt.org
(813) 745-0724

IMMUNOTHERAPIES

HDAC6: Method of Using Histone Deacetylase 6 Inhibition for Enhancing T cell Function During Anti-Tumor Response and Tumor-Peptide Vaccination	14MA037N
HDAC: Combination Therapy of Melanoma with an HDAC Inhibitor and a Checkpoint Inhibitor	14MA027N
S100A9: CD33/IgG1 Chimera Antibody Trap to Neutralize S100A9 to Treat MDS	13MB041
Vaccine: Vaccines Using Synthetic Peptide-Poly IC Complexes that Elicit T-cell Responses Comparable to Live Vaccination	11MA013
Antibodies: MARCO Antibodies for Enhanced Dendritic Cell Vaccine Efficacy	07MB004

PHARMACEUTICALS & BIOLOGICS

Small Molecule Inhibitor: 3-(4-fluorophenyl)-N-phenylbenzamide Small-Molecule Inhibitors of the β -Catenin/BCL9 Protein-Protein Interaction	22MA004N
Antibodies: Novel Targeted Nanobodies Against HPV E6/E7 to treat HPV Related Cancers	21MA047N
β-Catenin/BCL9: 1-Benzoyl 4-Phenoxypiperidines Small-Molecule Inhibitors of the β -Catenin/BCL9 Protein-Protein Interaction	21MA023
p53: Combination Therapy of Hypothermia and Chemotherapy to Treat Temperature Sensitive p53 Mutant Tumors	21MA021N
BRD4 JAK2: Sultam (cyclic sulfonamide) BRD4 JAK2 Inhibitors to treat myelofibrosis	21MA020N
JAK2: Novel JAK2 Inhibitor Piperadine Aniline Derivatives of Ruxolitinib to treat myelofibrosis	21MA004N
TROLLS: Inhibition Of TAp63 Regulated Oncogenic Long Noncoding RNAs (TROLLs) for the Treatment Of Cancer	20MB056N
β-Catenin/BCL-9: Acyl sulfonamide-containing Small Molecules that Inhibit the β -catenin/BCL9 Protein-Protein Interaction	20MB051N
HPV E1: Novel Use for Aminocoumarins as HPV Helicase E1 Inhibitors to Treat Cancer	20MB046
CMG Helicase: Novel Replicative CMG Helicase Inhibitors (CMGi) to Treat Solid Tumors	20MB046T2

Charlie Shaw PhD
Associate Director, Licensing
Charlie.Shaw@Moffitt.org
(813) 745-6639

Praba Soundararajan PhD
Intellectual Property Manager
Praba.Soundararajan@Moffitt.org
(813) 745-6776

Sayantan Purkayastha, MS
Industry Alliance Development Specialist
Sayantan.Purkayastha@Moffitt.org
(813) 745-0724

PHARMACEUTICALS & BIOLOGICS

TAF1: Novel TAF1 Inhibitors for the Treatment of Cancer	20MB037N
ACK1: Small molecule ACK1 inhibitors for the Treatment of Castrate Resistant Prostate Cancer	20MA015N
CDK12/CDK13: Novel Small Molecule Dual Inhibitors for CDK12/CDK13 for the Treatment of Triple Negative Breast Cancer	19MB064N
β-catenin/BCL9: Novel Small Molecules that Inhibit the β -catenin/BCL9 Interaction in breast cancer	19MB055
β-Catenin/TCF: Small Molecule Peptidomimetic Inhibitors of the Interaction of β -Catenin and T-Cell Factor	18MB076
BRD4 JAK2: Novel Second Generation BRD4/JAK2 Dual Inhibitors as Cancer Therapeutics	18MB053
β-Catenin/TCF: Small Molecule Inhibitors of the Interaction of β -Catenin and T-cell Factor	18MA018N
Ubiquitin Bispecific Antibody: Antibodies that Bring the E3 Ubiquitin Ligase into Close Proximity to Receptors to Induce the Receptor's Degradation	17MB056N
XBP-1: Method of XBP-1 Inhibition for the Treatment of Acute GVHD and Solid Organ Rejection	17MB051
β-Catenin/BCL-9: Small Molecule Inhibitors of the Interaction of β -Catenin and BCL-9	17MA014
HDAC, BTK: Method of Using HDAC Inhibitors, Alone or in Combination with BTK Inhibitors, for Treating Chronic Lymphocytic Leukemia (CLL)	16MA023N
Aurora/JAK2: Dual JAK2 and Aurora A Kinase Inhibitor for GVHD Prophylaxis	16MA005N
Ras/Raf: Stapled Peptides Designed to Inhibit the K-Ras/Raf Interaction	15MA012
Ras: Inhibitors of the Binding of GTP to Oncogenic Mutant K-Ras	15MA011
WEE1: Small Molecule WEE1 Inhibitor to Treat Cancer that Inhibits WEE1 Phosphorylation of H2B but not Cdc2	14MB092
YAP1/OCT4: Small Molecule Inhibitors of the Protein-protein Interaction of YAP1 and OCT4 to Treat Cancer	14MB075N
HDAC, BTK: Method of Using HDAC Inhibitors, Alone or in Combination with BTK Inhibitors, for Treating Non-Hodgkin's Lymphoma (NHL)	14MB086N
BRD4 JAK2: Novel BRD4/JAK2 Dual Inhibitors as Cancer Therapeutics	14MB069
Anti-Infectives: Symmetrical Synthetic Marinopyrroles as Anti-MRSA Therapeutics	12MB110
STAT3: STAT3 Dimerization Inhibitors	12MB098
IRE-1: Novel Small Molecule Inhibitors of IRE-1 for Treatment of B-Cell Cancer	12MB089

Charlie Shaw PhD
Associate Director, Licensing
Charlie.Shaw@Moffitt.org
(813) 745-6639

Praba Soundararajan PhD
Intellectual Property Manager
Praba.Soundararajan@Moffitt.org
(813) 745-6776

Sayantan Purkayastha, MS
Industry Alliance Development Specialist
Sayantan.Purkayastha@Moffitt.org
(813) 745-0724

PHARMACEUTICALS & BIOLOGICS

Mcl-1/Bcl-xL: Cyclic, Symmetrical and Asymmetrical Marinopyrroles as Anti-Cancer Agents	12MA035N
Proteasome: Non-Covalent and Reversible Proteasome Inhibitors with an Oxadiazole-Isopropylamide Core	10MB083
FT/GGT: Farnesyltransferase/ Geranylgeranyltransferase Dual Inhibitor	10MB048
LPAAT: Lysophosphatidic Acid Acyltransferase-Beta Inhibitors to Treat Pancreatic Cancer	10MA019N
Mcl-1: Asymmetrical Marinopyrroles as Anti-Cancer Agents	10MA018N
pH: Method of Inhibiting Metastasis with Systemic Non-Volatile Buffers to Reduce Intratumoral pH	09MB048

CLINICAL DECISION SUPPORT TOOLS

Aurora: Aurora A Kinase Inhibitors	09MA037
Rho Kinase: Pyridylthiazole-Based Ureas As Inhibitors of Rho Associated Protein Kinase (ROCK)	09MA015
Topoisomerase II: Method of Enhancing Topoisomerase II Inhibition by Inhibiting the Nuclear Export of Topoisomerase II Alpha	08MB014 10MB078
Machine Learning: A Rapid and Non-invasive Diagnostic to Predict PD-L1 Status Using Deep Learning Radiomics	19MB053
Math Model: A Radiomics Based Diagnostic to Predict Treatment Outcomes in Lung Cancer	19MB040N
Math Model: A Diagnostic that Predicts Treatment Outcome and Personalize CAR-T Therapies	19MA038N
Math Model: A Diagnostic that Predicts Efficacy and Progression Free Survival in CAR-T Treated Patients	19MA037N
Math Model: A Diagnostic for Lesion Heterogeneity Classification for Informed Treatment Decision	19MA034N
Software: Deep Neural Network to Locate and Label Brain Tumors Enables Surgeons to Remove Tumors More Effectively	19MA019
Math Model: Predict Patient-Specific Radiotherapy Responses Using a Proliferation Saturation Index in an Adaptive Bayesian Approach	18MB083N
Math Model: Methods for the Treatment of Prostate Cancer Using Intermittent Adaptive Therapy	18MB055N

Charlie Shaw PhD
 Associate Director, Licensing
 Charlie.Shaw@Moffitt.org
 (813) 745-6639

Praba Soundararajan PhD
 Intellectual Property Manager
 Praba.Soundararajan@Moffitt.org
 (813) 745-6776

Sayantan Purkayastha, MS
 Industry Alliance Development Specialist
 Sayantan.Purkayastha@Moffitt.org
 (813) 745-0724

CLINICAL DECISION SUPPORT TOOLS

Software: A Pathologist Tool for Alignment of Serial Whole Slide Histology Images	18MA012N
Software: A Quantitative Framework to Identify Radiation Targets for Cancer Treatment that Synergize with Immunotherapy (Abscopal Effect)	14MA022
Software: Decision Support Tool for Oncology Treatment Using Mathematical Simulations	13MB073
Software: Improved Detection of Lung Function and Management of Lung Cancer Radio Therapy	10MA037N

DIAGNOSTICS

Diagnostic: Kits and Methods for Performing an ELISPOT to Detect Coronavirus	21MA019N
Protein Diagnostic: Diagnostic to detect Leptomeningeal Disease	20MB040N
Molecular Imaging Agent: A Novel Fluorescence Molecular Imaging Agent for Intraoperative Margin Assessment in Breast Cancer	20MA008N
Cell Imaging: Diagnostic for Predicting Response to Therapies in Multiple Myeloma	19MB057 13MB048
Methylation Status Diagnostic: Diagnostic to Predict Response to Immunotherapy	19MB052
Companion Diagnostic: Companion Diagnostic to Predict Response to Immunotherapy Based on the Methylation Status	19MB052T2
Genetic Signature: Distinguishing Urothelial Carcinoma from Squamous Cell Carcinoma (Primary Lung Carcinoma and Metastatic Head & Neck Carcinoma)	17MB044
Genetic Biomarker: PTEN Loss of Expression as a Biomarker Response to GGTI-2418 Treatment	17MA025
Molecular Imaging: Predicting Response to Adjuvant Ipilimumab Treatment in Melanoma Using a Novel Algorithm to Analyze Nitric Oxide Levels in Peripheral Blood Immune Cells	17MA002N
miRNA Diagnostic: miRNA Signature for Non-invasive Early Detection of Malignancy in IPMN	17MA001
miRNA Diagnostic: Signature to Predict Progression of Barrett's Esophagus to Esophageal Dysplasia or Adenocarcinoma	16MB066
Molecular Imaging Probe: Novel IDO1-Targeting Cancer Diagnostic PET Imaging Agent	16MB044
Protein Biomarker: Predicting Restoration of Sensitivity to Erythropoietin in MDS Patients by Lenalidomide	16MB042

Charlie Shaw PhD
Associate Director, Licensing
Charlie.Shaw@Moffitt.org
(813) 745-6639

Praba Soundararajan PhD
Intellectual Property Manager
Praba.Soundararajan@Moffitt.org
(813) 745-6776

Sayantan Purkayastha, MS
Industry Alliance Development Specialist
Sayantan.Purkayastha@Moffitt.org
(813) 745-0724

DIAGNOSTICS

Protein Biomarker: Measuring MRE11 in Muscle-Invasive Bladder Cancer to Predict whether Cystectomy (Bladder Removal) would have a Better Outcome than Bladder-Sparing Therapy with Chemoradiation	16MB041
Genetic Signature: Distinguishing Primary Lung Carcinoma from Metastatic Head & Neck Carcinoma	16MB040
Protein Biomarker: Diagnostic for Progression of MDS to AML Using PD-1 or PD-L1 Expression	15MB065
Molecular Imaging Probe: In vivo Positron Emission Tomography-Based Perfusion/Blood Pool Imaging Using Labeled Erythrocytes	15MB042N
Diagnostic: S100A9 Serum Concentration Levels Predict Lenalidomide Response Duration	15MA031N
Diagnostic: Intracellular S100A9 Alone or NLRP3 Inflammasome Activation as MDS Biomarkers	15MA021N
Molecular Imaging: Monoacylated TLR2 Ligand Fluorescent Probe for Detection and Tumor Removal in Pancreatic Cancer Patients	15MA015
Genetic Signature: Microarray-Based Gene Expression Profiling to Predict Tumor Sensitivity to Radiotherapy	14MA052N
Protein Biomarker: Expression of WEE1 and PAXIP1 to Predict Respond to WEE1 Inhibitors	14MA001
miRNA Diagnostic: Blood Based microRNA Assay to Detect Malignant Intraductal Papillary Mucinous Neoplasms (IPMNs)	13MB078
Molecular Imaging: PET Probes of Radiofluorinated Carboximidamides for IDO-Targeted Imaging	13MB056N
Molecular Imaging: Novel Imaging Software Diagnostic to Determine Survival in Glioblastoma	13MB055
Molecular Imaging: Texture Features Low-Dose CT Images for Pulmonary Nodule Diagnosis	13MB054
Imaging: Decision Support Tool for Oncology Treatment that Analyzes Radiological Images	13MB047
Genetic Signature: Predicting Recurrence and Benefit From Adjuvant Chemo in Colorectal Cancer	13MA036
Multiplex Diagnostic: RNA Sequencing and Mass Spectrometric Method for Detecting Minimal Residual Disease in Multiple Myeloma	13MA009
Protein Diagnostic: Phosphorylated STAT3 Protein as a Biomarker of GVHD	13MA002
Molecular Imaging Probe: A Novel ¹⁸ F Scaffold for Preparing Targeted PET Imaging Probes	12MB104
Genetic Signature: E2F/Rb Pathway Signature to Predict Benefit from Adjuvant Chemo in NSCLC	12MA069
Protein Diagnostic: Quantum Dots Conjugated with Antibodies for Early Cancer Detection	12MA011N
Protein Diagnostic: Mass Spectrometry Diagnostic for BRAF and Heat Shock Proteins	11MB087N

Charlie Shaw PhD
 Associate Director, Licensing
 Charlie.Shaw@Moffitt.org
 (813) 745-6639

Praba Soundararajan PhD
 Intellectual Property Manager
 Praba.Soundararajan@Moffitt.org
 (813) 745-6776

Sayantana Purkayastha, MS
 Industry Alliance Development Specialist
 Sayantan.Purkayastha@Moffitt.org
 (813) 745-0724

DIAGNOSTICS

Genetic Signature: Predicting Response to Cancer Immunotherapy	11MB069
Molecular Imaging Probe: Intraoperative Detection of Pancreatic Cancer Using Targeted Fluorescent Probes	11MB064
Molecular Imaging Probe: Surrogate Markers for Colon Adenoma and Adenocarcinoma	11MA026N
Imaging: Digital Pathology Tool to Grade Breast Cancer Histological Images	11MA022
Protein Diagnostic: Protein-Protein Interaction (PPI) Biomarkers	11MA014
Molecular Imaging Probe: Fluorescent and MRI Targeted Probes for the Melanocortin Receptor 1 on Melanomas, and Micelle Complexes for Drug Delivery	10MB069N
Molecular Imaging Probe: Non-Invasive Detection of Breast Cancer in Lymph Nodes	10MA024
Genetic Signature: Lymph Node Formation for Prognosis of Colorectal Cancer	09MA014
Antibody Diagnostic: Monitoring Multiple Myeloma Progression and Recurrence	08MA005

DEVICES, TOOLS & SOFTWARE

Software: Cancer BERT Network (caBERTnet): A Question-and-Answer System to Extract Data from Free-Text Pathology Reports	21MA031
Med Device: A Single Customizable and Adaptive Ventilator Device to Treat Multiple Patients	20MA021
Life Science Tool: Diazirine reagents as Single and Double Nitrogen Transfer Reagents for Decarboxylative Amination	19MA030N
Med Device: Snowflake Shaped Drug Infusion Device for Brain Cancer	19MA010
Med Device: Biopsy Needle with Internal Ridges that Lead to a Higher Tissue Specimen Retrieval Rate	18MB047
Copyright: Energize mBC: Web-Based Program to Treat Fatigue in Metastatic Breast Cancer Patients	17MC003
Med Device: Novel Endotracheal Tube Intubating Stylet	16MA021
Med Device: Improved Pigtail Drainage Catheter for Percutaneous Fluid Aspiration	15MA034
Software: Negative Information Storage Model for Genomic Data	15MA033
Med Device: Expandable Intervertebral Cage for Spinal Fusion	14MB067N
Software: Real-Time Visualization Software Enables Surgeons to "See-Through" the Patient and Remove Tumors More Effectively	14MA004N

Charlie Shaw PhD
Associate Director, Licensing
Charlie.Shaw@Moffitt.org
(813) 745-6639

Praba Soundararajan PhD
Intellectual Property Manager
Praba.Soundararajan@Moffitt.org
(813) 745-6776

Sayantan Purkayastha, MS
Industry Alliance Development Specialist
Sayantan.Purkayastha@Moffitt.org
(813) 745-0724

DEVICES, TOOLS & SOFTWARE

Software: BMT Research Analysis Information Network (BRAIN) Automates Submission of AGNIS/CIBMTR Forms	13MB053
Software: Automated Technique for Generating BIRADS Scores from Mammograms	13MA025
Med Device: Improved Enteral Feeding Tube and Retention Disc to Reduce Dislodgement & Infection	13MA001
Software: Method for Improving the Accuracy of Charged Particle Beam Radiotherapy	12MB072
Med Device: Improved Endotracheal Tube to Diagnose Airway Edema (Swelling)	11MA052
Med Device: Bidirectional Expandable Intervertebral Cages for Spinal Fusion	11MA021T2
Med Device: Minimally Invasive Spinal Fusion Using a Transdiscal Screw System	11MA021
Med Device: Pump-Assisted High Flow Rate Isolated Limb Infusion for Regional Cancer Treatment	11MA017N
Med Device: Muscle Stapler	10MB065N
Med Device: Handheld Radioisotope Identification Device (RIID)	10MB054
Research Tool: Novel Electroporation Buffer Formulation for Enhanced Efficiency and Viability	05B141

Charlie Shaw PhD
 Associate Director, Licensing
 Charlie.Shaw@Moffitt.org
 (813) 745-6639

Praba Soundararajan PhD
 Intellectual Property Manager
 Praba.Soundararajan@Moffitt.org
 (813) 745-6776

Sayantan Purkayastha, MS
 Industry Alliance Development Specialist
 Sayantan.Purkayastha@Moffitt.org
 (813) 745-0724